Expression of gastrin-releasing peptide by excitatory interneurons in the mouse superficial dorsal horn by Gutierrez-Mecinas, Maria et al.
s 
 
 
 
Gutierrez-Mecinas, M., Watanabe, M., and Todd, A. J. (2014) Expression 
of gastrin-releasing peptide by excitatory interneurons in the mouse 
superficial dorsal horn. Molecular Pain, 10: 79. 
 
 
Copyright © 2014 The Author 
This work is made available under the Creative Commons Attribution 4.0 
License (CC BY 4.0)  
 
 
 
 
Version: Published 
 
 
 
http://eprints.gla.ac.uk/104812 
 
 
 
Deposited on:  09 April 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
MOLECULAR PAIN
Gutierrez-Mecinas et al. Molecular Pain 2014, 10:79
http://www.molecularpain.com/content/10/1/79RESEARCH Open AccessExpression of gastrin-releasing peptide by
excitatory interneurons in the mouse
superficial dorsal horn
Maria Gutierrez-Mecinas1, Masahiko Watanabe2 and Andrew J Todd1*Abstract
Background: Gastrin-releasing peptide (GRP) and its receptor have been shown to play an important role in the
sensation of itch. However, although GRP immunoreactivity has been detected in the spinal dorsal horn, there is
debate about whether this originates from primary afferents or local excitatory interneurons. We therefore examined
the relation of GRP immunoreactivity to that seen with antibodies that label primary afferent or excitatory interneuron
terminals. We tested the specificity of the GRP antibody by preincubating with peptides with which it could potentially
cross-react. We also examined tissue from a mouse line in which enhanced green fluorescent protein (EGFP) is
expressed under control of the GRP promoter.
Results: GRP immunoreactivity was seen in both primary afferent and non-primary glutamatergic axon terminals in
the superficial dorsal horn. However, immunostaining was blocked by pre-incubation of the antibody with substance P,
which is present at high levels in many nociceptive primary afferents. EGFP+ cells in the GRP-EGFP mouse did not
express Pax2, and their axons contained the vesicular glutamate transporter 2 (VGLUT2), indicating that they
are excitatory interneurons. In most cases, their axons were also GRP-immunoreactive. Multiple-labelling
immunocytochemical studies indicated that these cells did not express either of the preprotachykinin peptides,
and that they generally lacked protein kinase Cγ, which is expressed by a subset of the excitatory interneurons
in this region.
Conclusions: These results show that GRP is expressed by a distinct population of excitatory interneurons in
laminae I-II that are likely to be involved in the itch pathway. They also suggest that the GRP immunoreactivity
seen in primary afferents in previous studies may have resulted from cross-reaction of the GRP antibody with
substance P or the closely related peptide neurokinin A.Background
Itch is an aversive sensation, distinct from pain, which is
associated with the desire to scratch. Chronic itch is a
common and distressing condition associated with many
diseases and certain drug treatments [1], and often occurs
in the absence of obvious disease [2]. Since it is difficult to
treat, chronic itch represents a major unmet clinical need,
and there has therefore been considerable interest in the
peripheral and central mechanisms that underlie the per-
ception of itch [3,4].* Correspondence: Andrew.Todd@glasgow.ac.uk
1Institute of Neuroscience and Psychology, College of Medical, Veterinary
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article, unless otherwise stated.A major advance in our understanding came with the
finding that gastrin-releasing peptide (GRP, a member of
the bombesin family) and its receptor, gastrin-releasing
peptide receptor (GRPR) play an important role in itch
[5,6]. Specifically, it was shown that itch (but not pain)
behaviour was dramatically reduced in mice lacking
GRPR [5], and also in mice in which GRPR-expressing
neurons in the spinal cord had been ablated by intra-
thecal injection of bombesin conjugated to saporin [6].
It was also reported that GRP was present in a subset of
dorsal root ganglion (DRG) cells, identified by the pres-
ence of calcitonin gene-related peptide (CGRP) [5], which
is thought to be expressed by all peptidergic primary affer-
ents [7]. However, while it is generally accepted that GRP
is an important mediator if itch [3], there has been debateed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ample, several papers have reported that the level of GRP
mRNA is very low in the DRG [8-10], and it has been
suggested that the staining seen with GRP antibodies in
primary afferents represented cross-reaction with one of
two other peptides that are present in these afferents:
neuromedin B (NMB) or substance P [8,9].
There is also disagreement over whether dorsal horn
neurons express GRP. Although Sun and Chen [5] found
no GRP mRNA in the superficial dorsal horn of adult
mice, other published studies [8,10-15] and the Allen Brain
atlas [16] have reported numerous GRP mRNA-positive
cells in laminae I-II. These were found to be absent in mice
lacking the transcription factors Lmx1b, Tlx3 or Gsx1/2
[11,12,15], which are required for normal development of
the glutamatergic phenotype, suggesting that they were
excitatory interneurons [17-19]. In addition, many cells
containing enhanced green fluorescent protein (EGFP) are
seen in this region in a BAC transgenic mouse line from
the GENSAT project, Tg(GRP-EGFP), in which expression
of EGFP is under control of the GRP promoter [10]. How-
ever, Liu et al. [20] have recently questioned whether the
GRP mRNA in superficial dorsal horn neurons is trans-
lated into GRP.
Most (if not all) peptide-expressing primary afferents
contain CGRP [7], which is restricted to primary affer-
ents in the dorsal horn, and peptidergic primary afferent
terminals can therefore be identified by the presence of
CGRP [21,22]. The axons of glutamatergic interneurons
can be detected with antibodies against the vesicular
glutamate transporter 2 (VGLUT2), which is thought to
be expressed by all excitatory interneurons in this region
[23,24]. Despite the controversy over the source of
GRP-immunoreactive axons in the superficial laminae,
there have apparently been no studies to date in which
co-expression of GRP with either of these markers has
been investigated within the dorsal horn.
The main aim of this study was to determine whether
GRP-immunoreactivity could be detected in peptidergic
(CGRP+) afferent terminals and/or in VGLUT2+/CGRP−
boutons, which are likely to originate from local excita-
tory interneurons. Because many of the latter express
somatostatin [23-25] we looked for co-localisation of
GRP and somatostatin in VGLUT2-containing profiles.
We also tested the specificity of the GRP antibody by
pre-absorption with NMB and substance P. Finally, we
examined tissue from the GRP-EGFP mouse line, to look
for evidence that GRP was present in EGFP expressing
cells, and to provide an initial characterisation of these
cells.
Methods
All animal experiments were approved by the Ethical
Review Process Applications Panel of the University ofGlasgow and were performed in accordance with the
European Community directive 86/609/EC and the UK
Animals (Scientific Procedures) Act 1986.
Animals and general features of tissue processing
Three adult C57Bl/6 mice of either sex (21–24 g) and 2
Tg(GRP-EGFP) mice of either sex (21 g, 27 g) (GENSAT)
[10] were deeply anaesthetised with pentobarbitone
(30 mg i.p.) and perfused through the left ventricle with
fixative that contained 4% freshly depolymerised formalde-
hyde in 0.1 M PB. Lumbar spinal cord segments (L2-5)
were dissected out and stored for 1–5 hours in the same
fixative. They were then cut into transverse or sagittal sec-
tions with a vibrating-blade microtome and immersed in
50% ethanol for 30 mins to enhance antibody penetration.
Multiple-labelling immunofluorescence staining was
performed as described previously [26-28]. Briefly,
sections were incubated for 1–3 days in mixtures of
primary antibodies and then for 4–18 hours in species-
specific secondary antibodies that were raised in don-
key and conjugated to Rhodamine Red, Alexa 488,
Alexa 647, Pacific Blue or biotin (Jackson Immunore-
search, West Grove, PA, USA). All secondary anti-
bodies were diluted 1:500, apart from those conjugated
to Pacific Blue or Rhodamine Red, which were diluted
1:200 and 1:100, respectively. The biotinylated anti-
body was revealed with Pacific Blue conjugated to
avidin (1:1000; Life Technologies, Paisley, UK). All
antibodies were diluted in PBS that contained 0.3%
Triton X-100 and incubations were at 4°C. Following
the immunocytochemical reaction, sections were mounted
in anti-fade medium and stored at -20°C. Details of all pri-
mary antibodies used, their sources and concentrations
are given in Table 1.
Sections were scanned with a Zeiss LSM 710 confocal
microscope equipped with Argon multiline, 405 nm
diode, 561 nm solid-state and 633 nm HeNe lasers.
Scans were obtained through either a 63× or 40× oil-
immersion lens (numerical aperture 1.4 and 1.3, re-
spectively), with the aperture set to 1 Airy unit.
Co-localisation of GRP-immunoreactivity with other
axonal markers
Sections from the 3 wild-type mice were reacted with the
following combinations of primary antibodies: (1) rabbit
anti-GRP, goat anti-CGRP and guinea pig anti-VGLUT2,
or (2) rabbit anti-GRP, guinea pig anti-somatostatin and
goat anti-VGLUT2, and in each case these were revealed
with different fluorochromes. For each antibody combin-
ation, 3 sections were selected from each mouse before
the immunostaining was viewed at high magnification.
These were then scanned through the 63× oil-immersion
lens. z-stacks consisting of around 35 optical sections
(z-spacing 0.3 μm) were obtained from the middle part
Table 1 Primary antibodies used in this study
Antibody Species Catalogue no Dilution Source
GRP Rabbit BML-GA1166 lot # X09015 1:500 Enzo
CGRP Goat BML-CA1134 1:10,000 Enzo
VGLUT2 Rabbit 135 402 1:5,000 Synaptic Systems
VGLUT2 Guinea pig ab2251 1:5,000 Millipore
VGLUT2 Goat 1:500 M Watanabe
Somatostatin Guinea pig 1:1,000 P Ciofi
Substance P Rat OBT06435 1:200 Oxford Biotech
PPTB Guinea pig 1:1,500 P Ciofi
EGFP Chicken ab13970 1:1,000 Abcam
Pax2 Rabbit 716000 1:1,000 Life Technologies
PKCγ Guinea pig 1:500 M Watanabe
NeuN Mouse MAB377 1:500-1000 Millipore
Gutierrez-Mecinas et al. Molecular Pain 2014, 10:79 Page 3 of 15
http://www.molecularpain.com/content/10/1/79of the dorsal horn to include the whole dorsoventral
extent of laminae I-II.
The confocal image stacks from sections reacted to reveal
CGRP and VGLUT2 were analysed with Neurolucida for
Confocal software (MBF Bioscience, Williston, VT, USA).
The outline of the grey matter was drawn, and the ventral
border of the GRP plexus (which corresponded approxi-
mately to the boundary between the inner and outer parts
of lamina II) was determined from a maximum intensity
projection and plotted onto the drawing. A 4 × 4 μm grid
was then superimposed on the image stack. A section near
the middle of the z-series was initially viewed with only
the VGLUT2 and CGRP channels visible, and 100 boutons
that were VGLUT2-immunoreactive but lacked CGRP
(VGLUT2+/CGRP−) were selected from within the GRP
plexus by choosing the bouton nearest the bottom right
corner of successive grid squares, starting from a square
at the dorsal surface of the grey matter and progressing
through the squares in a dorsal-to-ventral, and then a
left-to-right, direction until the 100 boutons had been
acquired [29]. The GRP channel was then viewed and
the presence or absence of GRP-immunoreactivity was
recorded for each of the selected VGLUT2+/CGRP−
boutons. To compensate for bias towards larger profiles
in the selection process [30], the z-axis length of each
selected bouton was estimated by determining the number
of z-sections on which it was present [29].
In order to estimate the proportion of peptidergic
afferents that were labelled with the GRP antibody, we
then re-examined the sections and selected 100 CGRP+
boutons in the same way. These were then assessed for
the presence of GRP-immunoreactivity.
Since many glutamatergic interneurons in the superfi-
cial dorsal horn express the neuropeptide somatostatin
[23-25], we looked for evidence of co-expression of GRP
and somatostatin in VGLUT2-immunoreactive boutons.The level of VGLUT2 in peptidergic primary afferent
boutons is far lower than that seen in the axons of
neuropeptide-containing excitatory interneurons [23], and
we therefore initially viewed the channels representing
GRP and VGLUT2, and selected 50 boutons from each
section that were GRP-immunoreactive and had relatively
high levels of staining for VGLUT2 (axons of presumed
GRP+ local neurons). We then assessed these boutons for
the presence of somatostatin.
Specificity of GRP immunostaining
Since GRP shows considerable sequence similarity to NMB,
and it has been suggested that GRP-immunoreactivity in
the dorsal horn may in part result from cross-reactivity
with NMB [8], we tested whether the immunostaining
could be blocked with either GRP or NMB peptides
(Phoenix Pharmaceuticals, Burlingame, CA, USA). These
were added to anti-GRP antibody at its working concen-
tration (1:500) and the resulting solutions were stored for
18 hours at 4°C before the immunoreaction was started.
For each peptide, we tested 3 different concentrations:
10−5, 10−6 and 10-7 M. Sections were then incubated in
primary and fluorescent secondary antibody, as described
above.
In preliminary experiments, we had observed that if a
monoclonal antibody against substance P was included
in the primary antibody mixture, staining intensity with
the GRP antibody was consistently reduced (data not
shown). This raised the possibility that the GRP antibody
could cross-react with substance P (which is expressed
by many nociceptive primary afferents [31,32]), and that
this cross-reaction was reduced in the presence of sub-
stance P antibody, which would bind to substance P
and thus mask antigenic sites. We therefore also tested
the effect of pre-incubating the anti-GRP antibody with
substance P at 10−5, 10−6 and 10-7 M, as described above.
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We initially tested whether any GRP-EGFP cells were
inhibitory interneurons by looking for co-localisation
with the transcription factor Pax2, which is expressed by
GABAergic neurons in this region [17], and can readily
be detected in adult spinal cord sections [33,34]. Trans-
verse sections from L4 were reacted with chicken anti-
EGFP, rabbit anti-Pax2 and mouse monoclonal antibody
NeuN. Three sections from each mouse were scanned
through the 40× objective to produce z-stacks (20 optical
sections at 1 μm z-separation). The EGFP and NeuN
channels were initially viewed with Neurolucida. A thresh-
old was applied to allow identification of GRP-EGFP cells,
and the positions of these were marked on an outline of
the dorsal horn. The Pax2 channel was then switched on,
and the selected GRP-EGFP cells were assessed for the
presence or absence of Pax2.
Since we found that some EGFP-labelled profiles
resembled axonal boutons, we tested these for expression
of VGLUT2 and the vesicular GABA transporter (VGAT),
which are present in the boutons of excitatory and in-
hibitory interneurons, respectively [24]. We also deter-
mined the proportion of EGFP+ glutamatergic (VGLUT2+)
boutons that were GRP-immunoreactive, and the propor-
tion of GRP-immunoreactive non-primary glutamatergic
(GRP+/VGLUT2+) boutons that contained detectable
EGFP. Transverse sections from L4 were reacted with
chicken anti-EGFP, rabbit anti-GRP, guinea pig anti-
VGLUT2 and goat anti-VGAT, and these were revealed
with different fluorochromes as described above. Three
sections from each animal were scanned through the
63× lens to produce z-stacks (30–35 optical sections at
0.3 μm z-spacing) that included the central part of lam-
inae I-IIo. We initially looked for possible coexistence
of either GRP or EGFP with VGAT by examining the
entire z-series scanned from each section. We then
quantified the relationship between EGFP and GRP in
VGLUT2+ boutons. The channels corresponding to
VGLUT2 and EGFP were initially viewed with Neurolu-
cida, and 50 double-labelled boutons were identified in
each section. The channel corresponding to GRP was
then examined, and the presence or absence of GRP-
immunoreactivity in each of the selected boutons was
recorded. The sections were then re-analysed: 50 GRP+
boutons with strong VGLUT2 immunoreactivity were ini-
tially selected from each section and then the EGFP chan-
nel was viewed, and the presence or absence of EGFP in
each bouton was noted. In order to test for possible sam-
pling bias, we measured the z-axis lengths of a sample
of 60 boutons of each type (VGLUT2+/EGFP+/GRP+,
VGLUT2+/EGFP+/GRP− and VGLUT2+/EGFP-/GRP+), by
selecting 10 of each type from each of the sections analysed.
Since we found evidence that the GRP antibody may
cross-react with substance P (see below), we wereconcerned that the GRP immunoreactivity that we de-
tected in EGFP+ axons could have resulted from binding
of the antibody to a tachykinin peptide (substance P, neu-
rokinin A or neurokinin B). These peptides, which share
the same C-terminal amino acid sequence, are derived
from two different genes, which code for preprotachykinin
A (PPTA, which gives rise to both substance P and neuro-
kinin A, NKA) and preprotachykinin B (PPTB, which gen-
erates neurokinin B, NKB). PPTA and PPTB are expressed
by largely non-overlapping populations of excitatory neu-
rons in the superficial dorsal horn [35-38], while PPTA
(but not PPTB) is expressed by many nociceptive primary
afferents [31,32,39,40]. We therefore reacted transverse
sections from the L2 segment with chicken anti-EGFP,
rabbit anti-VGLUT2, rat anti-substance P and guinea pig
anti-PPTB. One section from each animal was scanned
through the 40× lens to generate a z-stack of ~20 optical
sections at 0.5 μm z-spacing. These were opened in
Neurolucida for confocal, with only the EGFP and VGLUT2
channels visible, and 100 EGFP+/VGLUT2+ boutons were
selected from each animal. The channels corresponding to
substance P and PPTB were then viewed, and the presence
or absence of these peptides was noted for each of the
selected boutons.
Because some excitatory interneurons in the superfi-
cial dorsal horn express protein kinase Cγ (PKCγ) [41],
we tested whether this population included any of the
GRP-EGFP cells. Transverse sections of L4 were reacted
with chicken anti-EGFP, guinea pig anti-PKCγ and
mouse monoclonal antibody NeuN. Three sections from
each mouse were scanned through the 40× lens to produce
z-series (20 sections, 1 μm z-separation) that covered the
entire width of the superficial dorsal horn. The EGFP and
NeuN channels were initially viewed with Neurolucida, and
GRP-EGFP cells were selected as described above. The
PKCγ channel was then examined, and the proportion of
GRP-EGFP cells that were PKCγ+ was determined.
Finally, since populations of interneurons in the superfi-
cial dorsal horn have been classified based on morphology
[24,34,42-48], we carried out a preliminary survey of the
morphology of the GRP-EGFP cells by reacting sagittal
sections through the L3 segment of both animals with
chicken anti-EGFP. Three sections from each animal were
scanned with the 40× lens through the full thickness of
the section to produce z-stacks of 0.5 μm z-separation.
These were examined in the original z-series, and also as
maximum intensity projections.
Characterisation of antibodies
The GRP antibody was raised against the C-terminal se-
quence [14-27] of human GRP (MYPRGNHWAVGHLM)
conjugated to bovine serum albumin (BSA) with glutaral-
dehyde. This sequence is identical to that of the corre-
sponding region of mouse GRP, apart from a single amino
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was directed against synthetic rat α CGRP conjugated to
BSA, and is blocked by pre-incubation with the incubating
peptide at 10−7 M (manufacturer’s specification). The
guinea pig, rabbit and goat antibodies against VGLUT2
were raised against peptides corresponding to amino
acids 565–582 of rat VGLUT2 (guinea pig antibody)
and amino acids 510–582 (rabbit antibody) or 550–582
(goat antibody) of mouse VGLUT2, respectively. The
guinea pig antibody stains identical structures to the
rabbit antibody [23], and both goat and rabbit antibodies
detect a single protein band of the appropriate molecular
weight (60 kDa) [49,50]. The somatostatin antibody was
raised against residues 1–12 of somatostatin-24, and de-
tects identical structures to those labelled with a different
somatostatin antibody, raised in rabbit [51]. The monoclo-
nal substance P antibody detects the C-terminal 5–8Figure 1 The relationship between GRP, CGRP and VGLUT2 in lamina
(blue) and VGLUT2 (red) in a projection of two confocal sections (0.5 μm z-se
of GRP immunoreactivity resembles that of CGRP, and many profiles are doub
GRP-immunoreactive profiles that lack CGRP and are strongly stained with the
Scale bar = 50 μm.amino acids of the peptide [52], and does not appear to
recognise NKB when used at concentrations sufficient to
reveal substance P [35,38]. The PPTB antibody was raised
against a synthetic 40 amino acid peptide corresponding
to residues 50–79 of PPTB, which was conjugated to hu-
man serum albumen with glutaraldehyde [53]. Immuno-
staining with this antibody is blocked by preincubation
with the immunising peptide, but not by preincubation
with substance P, NKA or NKB [53]. This antibody was
used as it allows the identification of cells that express
PPTB, and therefore presumably release NKB. The EGFP
antibody was raised against recombinant full-length EGFP,
while the antibody against Pax2 was raised against amino
acids 188–385 of the mouse protein. The guinea pig anti-
body against PKCγ was raised against the C terminal 14
amino acids of the mouse protein and recognises a single
band of the appropriate molecular weight on Westerne I-II. a-c, Immunostaining with antibodies against GRP (green), CGRP
paration). d shows a merged image. At this magnification, the distribution
le-labelled (some shown with arrowheads). However, there are also
VGLUT2 antibody, and three of these are indicated with arrows.
Figure 2 High magnification view of GRP, CGRP and VGLUT2 in the superficial dorsal horn. a-c, Immunostaining with antibodies against
GRP (green), CGRP (blue) and VGLUT2 (red) in a single optical section. d shows a merged image. Several GRP-immunoreactive profiles are visible
in this field. Two of these are CGRP+ and are stained very weakly with the VGLUT2 antibody (arrowheads), while several lack CGRP but show
strong VGLUT2 immunoreactivity (three indicated with arrows). Scale bar = 10 μm.
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PKCγ−/− mice [54]. The mouse monoclonal antibody
NeuN was raised against cell nuclei extracted from
mouse brain [55] and apparently labels all neurons but
no glial cells in the rat spinal dorsal horn [56].
Statistics
Differences in the z-axis lengths of different neurochem-
ical types of axonal bouton were compared by using either
a t-test or one-way ANOVA.
Results
Immunostaining with GRP antibody in the dorsal horn
Immunostaining with the GRP antibody resembled that
reported in previous studies with antibodies against GRP
or bombesin [5,8,57]. There was a dense band of staining
in the superficial part of the dorsal horn, mainly in lam-
inae I-IIo, and this was restricted to structures that resem-
bled axons (Figure 1). No GRP immunoreactivity was seen
in cell bodies.
In sections reacted with antibodies against GRP, CGRP
and VGLUT2, we found numerous boutons that were im-
munoreactive for both GRP and CGRP, and these typically
showed strong GRP immunoreactivity. However, we alsoFigure 3 Co-localisation of somatostatin and GRP in axons with stron
against GRP (green), somatostatin (Som, blue) and VGLUT2 (red) in a projec
image. Several profiles showing all three types of immunoreactivity are visi
Scale bar = 5 μm.identified many GRP-immunoreactive profiles that lacked
CGRP, and these were frequently immunoreactive with
the VGLUT2 antibody (Figures 1 and 2). Quantitative ana-
lysis revealed that GRP immunoreactivity was present in
70.1% (range 66.7-75.7%, n = 3 mice) of CGRP+ boutons
in laminae I-IIo. As reported previously [23], we found
that VGLUT2 immunoreactivity in CGRP+ boutons was
either very weak or undectable, even though all primary
afferents are thought to be glutamatergic [58,59]. GRP
immunoreactivity was seen in 30.2% (27.3-32%) of the
VGLUT2+/CGRP− profiles in laminae I-IIo, and the inten-
sity of GRP labelling in these was often lower than that
seen in the CGRP+ profiles. The mean z-axis length of
GRP+/VGLUT2+ boutons was 1.53 ± 0.51 (n = 276 bou-
tons), while that of the GRP-/VGLUT2+ boutons was
1.48 ± 0.47 (n = 624 boutons). These were not signifi-
cantly different (p = 0.19, t-test), suggesting that our
estimate was unlikely to be affected by a sampling bias
towards larger boutons.
In the sections reacted for GRP, VGLUT2 and somato-
statin, 70.2% (68-72%) of the GRP+/VGLUT2+ boutons
in laminae I-IIo (axons of presumed GRP+ local neurons,
see above) were somatostatin-immunoreactive (Figure 3).
The sizes of boutons with and without somatostating VGLUT2 immunoreactivity. a-c, Immunostaining with antibodies
tion of 5 confocal sections (0.3 μm z-separation). d shows a merged
ble in this field, and 3 of these are indicated with arrows.
Figure 4 The effect of pre-incubating the GRP antibody with
GRP and NMB. a, Immunostaining with the GRP antibody in the
superficial dorsal horn from a transverse section. b, An equivalent
field from a section in which the GRP antibody had been
preincubated with GRP at 10−7 M overnight. c, Staining with
antibody that had been preincubated with NMB at 10−5 M
overnight. Note that preincubation with GRP completely blocked
specific staining, whereas the staining was not affected by NMB.
Scale bar = 20 μm.
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were not significantly different (p = 0.06).
To test for the possibility that GRP immunoreactivity
in peptidergic primary afferents represented a cross-
reaction with either NMB [8] or a tachykinin peptide
[9], we pre-incubated the anti-GRP antibody with either
GRP, NMB or substance P, as described above. Pre-
incubating the anti-GRP antibody with GRP completely
blocked immunostaining, even at the lowest concentration
tested (10−7 M), whereas immunostaining was not affected
by pre-incubation with NMB, even at the highest concen-
tration tested (10−5 M, Figure 4). Pre-incubation with sub-
stance P at 10−5 M largely blocked GRP immunostaining,
and this was also reduced at 10−6 and 10−7 M (Figure 5).
GRP-EGFP cells
As described by Mishra and Hoon [10], numerous EGFP+
cells were present in the dorsal horn of the GRP-EGFP
mice, and these were concentrated in laminae I-II, with
scattered cells present in the deeper laminae (Figures 6Figure 5 The effect of pre-incubating the GRP antibody with differen
antibody in lamina I-IIo from a transverse section. b-d, Equivalent fields from
overnight with different concentrations of substance P. Note that staining
absent at 10−6 and 10−5 M. Scale bar = 20 μm.and 7). The laminar distribution could be seen best in the
transverse sections that had been reacted for PKCγ
(Figure 6), as the plexus of PKCγ-immunoreactive dendrites
can be used to define the inner half of lamina II [60]. As re-
ported previously [10], we did not see EGFP-positive cells
in the dorsal root ganglia of these mice (data not shown).
Altogether, 180 EGFP cells were identified in the
superficial dorsal horn in sections reacted for Pax2 and
NeuN (125 and 55 cells in the 2 mice), and none of
these was Pax2-immunoreactive (Figure 8), indicating
that they are unlikely to be inhibitory interneurons.
Interestingly, the staining for NeuN in the GRP-EGFP
cells was consistently weak, compared to that seen in
many EGFP-negative neurons. The consistently low
level of NeuN probably reflects the fact that the GRP
cells originate form a distinct developmental popula-
tion, and has also been observed for γ-motoneurons in
the ventral horn [61].
In the sections reacted to reveal EGFP, GRP, VGLUT2
and VGAT, numerous boutons with VGLUT2 or VGAT
were present, and these formed non-overlapping popu-
lations. As described above, we found that GRP and
VGLUT2 were frequently co-localised in boutons,
whereas co-localisation of GRP and VGAT was extremely
rare (only 6 examples of GRP+/VGAT+ profiles were
seen throughout the full depth of the 6 z-stacks ana-
lysed in this part of the study, and we estimate that this
corresponds to around 0.1% of the GRP boutons). This
supports the suggestion that GRP expression by superficial
dorsal horn neurons is largely restricted to those that are
excitatory [11]. EGFP was never co-localised with VGAT in
these sections, providing further evidence that the EGFP
cells were not inhibitory interneurons. In contrast, EGFP
and VGLUT2 were frequently colocalised (Figures 9 and
10). GRP-immunoreactivity was detected in 72.3% (69.3%
and 75.3% in the two mice) of the profiles that contained
both EGFP and VGLUT2. Conversely, EGFP was seen in
41.7% (46%, 37.3%) of profiles that were immunoreactive for
both VGLUT2 and GRP. The mean z-axis lengths of
EGFP+/GRP+, EGFP+/GRP− and EGFP−/GRP+ boutons in
this sample were 1.88 μm± 0.51 μm, 1.83 μm± 0.44 μmt concentrations of substance P. a, Immunostaining with the GRP
sections incubated in GRP antibody that had been preincubated
is diminished by preincubation with 10−7 M substance P, and largely
Figure 6 (See legend on next page.)
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(See figure on previous page.)
Figure 6 Distribution of EGFP cells in the GRP-EGFP mouse. a, Immunostaining for EGFP (green) in a transverse section shows scattered cell
bodies throughout laminae I-II (projection of 20 optical sections at 1 μm z-spacing). The outer dashed line represents the outline of the dorsal
horn, while the region between inner two lines corresponds to the inner half of lamina II, as defined by the plexus of PKCγ+ dendrites. b shows
the same field scanned to reveal EGFP and PKCγ (magenta). Note that these are expressed in largely non-overlapping neuronal populations. c-e,
Immunostaining with antibodies against EGFP (green) and PKCγ (magenta) showing the inner part of lamina II in a single optical section. Two
EGFP+ cells that show weak PKCγ-immunoreactivity are indicated with arrowheads, and an EGFP+ cell that lacks PKCγ is marked with an arrow.
Scale bars = 100 μm (a,b) and 20 μm (c-e).
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(one-way ANOVA, p = 0.49), indicating that our results
were not likely to have been affected by a sampling bias
due to size differences between the different populations.
In sections reacted to reveal EGFP, VGLUT2, substance
P and PPTB, we found virtually no expression of either
substance P or PPTB among the EGFP+/VGLUT2+ bou-
tons (Figure 10). Only 1 of the 200 selected boutons was
also immunoreactive for PPTB, and none for substance
P. Although many VGLUT2 boutons showed either
substance P or PPTB immunoreactivity, we found very
few that were stained for both peptides (as reported
previously for the rat [35,38]). Since NKA is apparently
restricted to neurons that also express substance P [62],
the lack of either SP or PPTB immunoreactivity in the
boutons of the GRP-EGFP cells indicates that the GRP im-
munoreactivity that we observed in them is not due to
cross-reactivity with a tachykinin peptide, and is therefore
likely to be genuine.
In the sections reacted for PKCγ, there was some
overlap in the distribution of EGFP+ and PKCγ+ cells
in lamina IIi, although many EGFP+ cells were located
dorsal to the main band of PKCγ+ cells (Figure 6). In
these sections, 112 EGFP cells were selected in one
animal and 73 in the other. The great majority of the
EGFP cells were not PKCγ-immunoreactive, although aFigure 7 Appearance of EGFP cells in the GRP-EGFP mouse in sagitta
image through full thickness of a 60 μm section) reveals the dense band of G
Note that the cells are morphologically diverse, with no obvious characteristic
tical sections at 0.5 μm z-spacing) from a different section shows an EGFP-l
directed dendrites, which could be classified as a vertical cell. Scale bar =few (15.2% and 9.6%, respectively) showed weak PKCγ
immunoreactivity (Figure 6c-e).
Numerous EGFP-labelled cells were seen in the sagittal
sections, and these varied considerably in the strength of
staining (Figure 7). For strongly labelled cells it was
possible to follow dendritic trees for some distance,
and dendritic spines could easily be identified. The
EGFP-labelled cells were morphologically heterogeneous,
and in most cases dendrites were orientated along the ros-
trocaudal axis or travelled obliquely in both rostrocaudal
and dorsoventral axes. A small number of EGFP-labelled
neurons resembled vertical cells, and an example is shown
in Figure 7 (inset).
Discussion
The main findings of this study are: (1) that immuno-
staining with a GRP antibody is present in both pri-
mary afferents and non-primary glutamatergic axons
in the superficial dorsal horn, (2) that immunostaining
is partially blocked by pre-incubation with substance P,
but not with NMB, (3) that EGFP-labelled cells in the
GRP-EGFP mouse line are Pax2-negative, with most
lacking PKCγ, and (4) that many of the axons derived
from EGFP-labelled cells in this line express detectable
levels of GRP-immunoreactivity, but are not immuno-
reactive with antibodies against substance P or PPTB.l section. Immunostaining for EGFP in a sagittal section (projected
RP-EGFP cells that occupy laminae I-II, with scattered cells below this level.
orientation of their proximal dendrites. Inset: a projected image (26 op-
abelled cell with ventrally
100 μm for main image, 20 μm for inset.
Figure 8 Lack of Pax2 in EGFP cells in the GRP-EGFP mouse. a-c, Immunostaining with antibodies against EGFP (green), Pax2 (blue) and
NeuN (red) in a single optical section. d shows a merged image. Several EGFP+ cells, all of which are Pax2− are visible, and 3 of these are marked
with arrows. Note the very weak NeuN staining in these cells, compared to that seen in other nearby neurons, including those that are Pax2+,
some of which are indicated with arrowheads. Scale bar = 50 μm.
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dorsal horn
Our finding that GRP immunoreactivity could be detected
in the majority of CGRP+ axons in laminae I-IIo is consist-
ent with several previous reports that other antibodies
raised against GRP or the related peptide bombesin stain
cell bodies of peptidergic primary afferents in the dorsal
root ganglion [5,57,63-66], and that there is significant de-
pletion of immunostaining in the dorsal horn following
dorsal rhizotomy [8,57]. However, although GRP mRNA
has been identified in dorsal root ganglion cells with in
situ hybridisation and the polymerase chain reaction by
the Chen laboratory [5,20], studies from two other groups
have failed to detect significant levels of the mRNA in dor-
sal root ganglia using either these methods or quantitative
RNA sequencing [8-10]. The question of whether GRP is
actually expressed in primary afferents therefore remains
controversial. Fleming et al. [8], noting the high level of
expression of NMB in dorsal root ganglia and the close se-
quence similarity between NMB and GRP, suggested that
much of the GRP immunoreactivity identified in primaryafferents could result from cross-reaction of the GRP anti-
bodies with NMB. However, we found that relatively high
concentrations of NMB (10−5 M) were unable to block
immunostaining with our anti-GRP antibody, even though
this was completely blocked by GRP at 100 times this
dilution (10−7 M). It is therefore unlikely that the primary
afferent staining that we saw with anti-GRP represents a
cross-reaction with NMB. Goswami et al. [9] suggested
that GRP antibodies might cross-react with tachykinin
peptides, such as substance P, which are highly expressed
in primary afferents, and which show some similarity in
their C-terminal amino acid sequence to GRP (−GLM in
tachykinin peptides, compared to -GHLM in GRP and
-GHFM in NMB). In addition, we had found in prelimin-
ary studies that including anti-substance P in the primary
antibody mixture reduced the staining for GRP in these
sections (MGM and AJT, unpublished data). We therefore
tested the effects of pre-incubating with substance P on
the staining seen with the GRP antibody, and found that
this was suppressed. Although we cannot be certain that
the GRP antibodies would bind to substance P in fixed
Figure 9 GRP expression in EGFP cells in the GRP-EGFP mouse. a-c, Immunostaining with antibodies against EGFP (green), GRP (red) and
VGLUT2 (blue) in a projected confocal image (4 optical sections at 0.3 μm z-spacing). d shows a merged image. Four profiles showing all three types
of immunoreactivity are marked with arrowheads. Scale bar = 5 μm.
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GRP-like immunoreactivity seen in peptidergic primary
afferents in this study may represent a cross-reaction
with substance P or the closely related peptide NKA. It
is also possible that previous reports of primary afferent
labelling with different GRP antibodies [5,57,63-66] may
have resulted, at least in part, from cross-reaction with
tachykinin peptides. This could be tested in future studies
by analysis of tissue from mice in which the gene for
PPTA has been knocked out [67].
GRP-immunoreactivity was also detected in boutons
that were VGLUT2+ but lacked CGRP, and most of
these are likely to originate from local excitatory in-
terneurons [23,24]. Consistent with this suggestion,
we found that somatostatin, which is expressed by
many excitatory interneurons in the superficial dorsal
horn [25], was frequently co-localised with GRP in
VGLUT2+ axons. It is likely that at least some of this
represents genuine GRP, as it was sometimes co-localised
with EGFP in axonal boutons in the GRP-EGFP mouse,
and these cells did not express either of the two
preprotachykinins.
Since only ~40% of the GRP+/VGLUT2+ boutons in
this mouse line were immunoreactive for EGFP, it is
possible that the staining in other non-primary (i.e.
VGLUT2+/EGFP−) axonal boutons resulted from cross-
reaction of the GRP antibody with tachykinin peptides,which are expressed by many excitatory neurons in this
region [35-37]. However, the failure to detect EGFP in
these boutons may alternatively have resulted from weak
expression (or lack of expression) of EGFP in some GRP-
containing cells in this BAC transgenic line.
GRP-expression by excitatory interneurons
Several studies have reported that large numbers of cells
with GRP mRNA are present in the superficial dorsal
horn [8,10-15]. It has also been shown that these are
likely to be excitatory neurons, since their survival is
dependent on expression of transcription factors that
are involved in determining a glutamatergic phenotype
[11,12,15]. In addition, it has been reported that most of
the GRP-expressing cells are lost in mice lacking the
testicular orphan nuclear receptor (TR4), in which there
is preferential depletion of excitatory interneurons [14].
However, Liu et al. [20] recently claimed that cells with
GRP mRNA were restricted to lamina I and state that
“to date, little evidence exists to support that Grp
mRNA in lamina I of the spinal cord is in fact translated
into GRP protein”. This statement was apparently based
on the failure of immunocytochemical studies to dem-
onstrate GRP-immunoreactivity within cell bodies in
the superficial dorsal horn. However, although some of
the neuropeptides expressed by neurons in this region
can be identified in their cell bodies with
Figure 10 Lack of co-localisation of EGFP and either substance
P or PPTB in glutamatergic boutons in the GRP-EGFP mouse. a
Immunostaining with antibodies against EGFP (green), substance P
(SP, red) and PPTB (blue) in a single optical section through lamina II
from the L2 segment of one of the GRP-EGFP mice. b shows the
same field scanned to reveal VGLUT2 (grey). c a merged image.
Several VGLUT2-immunoreactive profiles that also stain for EGFP are
visible, and 3 of these are indicated with arrows. These are not
stained for either substance P or PPTB. Other VGLUT2 boutons that
are stained with the substance P or PPTB antibodies are also present
in this field, and some of these are marked with arrowheads or
double arrowheads, respectively. Scale bar = 10 μm.
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stance P, NKB, dynorphin or the enkephalins are either
not detected, or else are seen in very few cells. The failure
to detect somatic staining for these peptides results from
rapid transport of the peptide out of the cell body, and
for this reason colchicine was administered in several
early studies to prevent axoplasmic transport, therefore
elevating the levels of neuropeptides in cell bodies
[71,72].
Our finding that ~70% of the axon terminals that
contained EGFP in the GRP-EGFP mouse were GRP-
immunoreactive (and that they lacked tachykinins,
with which the GRP antibody can cross-react) strongly
suggests that these cells are indeed translating the
mRNA into GRP. The lack of immunoreactivity in theother ~30% of EGFP+/VGLUT2+ boutons may reflect
variable levels of GRP expression, with some axons
containing amounts below the detection threshold of
the GRP antibody. Alternatively it could result from
ectopic expression of EGFP in this line. However, even
if there is ectopic EGFP expression, it is evidently not ran-
dom, as it seems to be restricted to excitatory (Pax2−)
cells.
Excitatory interneurons account for ~70% of the neu-
rons in the superficial dorsal horn [73], and are thought to
include several distinct subpopulations that are likely to
have differing roles in the processing of sensory informa-
tion [14,59,74-76]. Several attempts have been made to
define these functional populations, using morphological,
electrophysiological, neurochemical and/or developmental
approaches [12,24,34,44-47,77-79]. Although the neurons
in this region are morphologically diverse, certain dis-
tinctive classes have been identified among the excitatory
cells in lamina II. These include vertical cells, which have
dendrites that project ventrally from the soma and an
axon that often enters lamina I where it may be presynap-
tic to projection neurons, and radial cells, which are small
and have short radiating dendrites [24,34,44-47,80]. A
third morphological group (central cells), has also been
described [34,44-46]. These have relatively short dendritic
trees orientated along the rostrocaudal axis. However,
central cells are a more diverse set that includes both
excitatory and inhibitory interneurons [24]. A limitation
of this scheme is that all morphological studies have
found a significant fraction of lamina II interneurons
(typically ~25%) that cannot be be assigned to any of
these morphological classes [24,34,44-46]. Based on the
appearance of GRP-EGFP cells in sagittal sections, most
did not appear to be vertical or radial cells, and so they
are likely to belong to central or unclassified populations.
A neurochemical approach has proved useful in defining
functional subsets among the inhibitory interneurons in
the superficial dorsal horn. For example, we have identi-
fied four largely non-overlapping populations, those that
express neuropeptide Y (NPY), galanin, neuronal nitric
oxide synthase (nNOS) and parvalbumin, and found that
these differ in their responses to noxious stimulation [27].
Many of the cells that contained NPY or galanin were
activated by noxious heat, as well as by subcutaneous
injection of formalin or capsaicin. In contrast, the
nNOS-containing cells responded to noxious heat and
formalin injection, but seldom to capsaicin, while the
parvalbumin cells were not activated by any of these
stimuli. In addition, it has been shown that the
parvalbumin-expressing cells give rise to axoaxonic
synapses on myelinated low-threshold mechanorecep-
tive afferents [81], while the nNOS and/or galanin popu-
lations have been implicated in the suppression of itch by
counterstimuli [33].
Gutierrez-Mecinas et al. Molecular Pain 2014, 10:79 Page 13 of 15
http://www.molecularpain.com/content/10/1/79Several neurochemical markers are expressed by sub-
sets of excitatory neurons, and it would be of value if we
could also define non-overlapping populations among
these cells. It had already been shown that there is little
co-localisation of PPTB and substance P in axons in
laminae I-II [35,38], and taken together with the results
of this study, it therefore appears that different sets of
excitatory neurons express PPTA, PPTB and GRP. Neu-
rotensin is also present in some excitatory neurons in
laminae IIi-III [23,82]. These are known to be different
from those that express PPTB [35], and we have found
little or no co-localisation of neurotensin and substance
P (MGM and AJT, unpublished data). Since most of the
neurotensin-containing cells also express PKCγ [41], it is
likely that they are largely separate from the cells with
GRP, as the EGFP+ cells seen in this study were generally
PKCγ-negative. This suggests that there may be four
distinct neuropeptide-expressing populations among the
excitatory neurons in laminae I-III: those with PPTA,
PPTB, GRP and neurotensin. Since the axonal boutons
of these cells can be recognised by co-localisation of the
corresponding peptide with VGLUT2, it should be pos-
sible to use immunocytochemistry to investigate the
postsynaptic targets for each population. Nothing is
apparently known yet about the responses of the GRP-
expressing interneurons to peripheral stimuli, but as
GRP and the GRPR have been implicated in itch [5,6],
it will be important to determine whether the GRP-
expressing neurons in laminae I-II are activated by
pruritic stimuli.
Conclusions
The results of the present study indicate that GRP is
expressed by at least some of the neurons that contain
EGFP in the GENSAT mouse line Tg(GRP-EGFP). They
also show that these cells are excitatory interneurons,
and are largely different from those that express PPTA,
PPTB or PKCγ. In addition, they raise the possibility that
some of the GRP immunoreactivity seen in this and pre-
vious studies may have resulted from a cross-reaction
with substance P and/or NKA.
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